Amid supply-chain woes Computer - Integrated Systems players like IBM, HPE and AGYS benefit from integrated solutions demand and multi-cloud model adoption. We recently published a list of 10 Mid ...

IBM is over a century old, a massive multinational even before the dawn of the computer age. Through research and innovation, IBM came to dominate the nascent market for mainframe computers, parlaying ...

If you're seeking the ultimate PC gaming experience without breaking the bank, these cheap gaming PC deals could be precisely what you need. They balance performance and affordability perfectly ...

I'd say now is the perfect time to hunt for the best cheap gaming PC deals, as the arrival of new RTX 50-series graphics cards could result in RTX 4000 price cuts. While GPUs like the RTX 4090 ...

If you've bagged yourself a gaming laptop, PC gaming handheld or anything of the like, congratulations — you can now play an ever-growing catalog of the best PC games around. From thrilling ...

There are so many exciting upcoming PC games on the way in 2025. From sprawling, highly anticipated RPGs to third-person shooters and story-driven experiences, we've brought together the biggest ...

When is Stellar Blade coming to PC? Developer Shift Up originally planned to bring Stellar Blade (previously known as Project Eve) to PC when it was revealed back in 2019, but Sony’s involvement ...

And if you've decided you're more into getting yourself a desktop bargain, we've compiled a list of the best cheap gaming PC deals, too.

I have been a technology journalist for 30-plus years and have covered just about every kind of computer gear—from the 386SX to 64-core processors—in my long tenure as an editor, a writer ...

Andrei has received distinguished paper awards at the last three Principle of Programming Languages (POPL) conferences, one of the most prestigious conferences in Computer Science. Congratulations to ...

Bristol-Myers Squibb has become the latest drugmaker in the US to file a legal challenge to a block on a drug rebate model opposed by a Health and Human Services (HHS) department. Specifically ...

It's worth noting that this isn't Pfizer's first deal in SCD. In 2011 it paid $340 million for rights to rivipansel, a pan-selectin antagonist developed by GlycoMimetics, which failed a phase 3 ...